Alumis (ALMS) News Today $4.31 -0.40 (-8.49%) As of 04/24/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period HC Wainwright Issues Pessimistic Forecast for Alumis (NASDAQ:ALMS) Stock PriceHC Wainwright cut their price target on shares of Alumis from $15.00 to $14.00 and set a "buy" rating for the company in a report on Tuesday.April 24 at 8:11 AM | marketbeat.comHC Wainwright Has Lowered Expectations for Alumis (NASDAQ:ALMS) Stock PriceApril 24 at 1:35 AM | americanbankingnews.comAlumis Sees Unusually Large Options Volume (NASDAQ:ALMS)Alumis Inc. (NASDAQ:ALMS - Get Free Report) was the target of unusually large options trading activity on Monday. Stock investors bought 5,003 call options on the company. This represents an increase of 147% compared to the typical daily volume of 2,026 call options.April 23 at 11:40 AM | marketbeat.comAlumis price target lowered to $14 from $15 at H.C. WainwrightApril 22 at 8:59 PM | markets.businessinsider.comTraders Purchase Large Volume of Alumis Call Options (NASDAQ:ALMS)April 22 at 1:40 AM | americanbankingnews.comAlumis and Acelyrin sign ammended merger agreementApril 21, 2025 | markets.businessinsider.comAlumis, ACELYRIN amend proposed merger pactApril 21, 2025 | msn.comACELYRIN, INC. Amends Merger Agreement with AlumisApril 21, 2025 | tipranks.comAlumis and ACELYRIN Announce Amended Merger AgreementApril 21, 2025 | globenewswire.comACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRNApril 16, 2025 | businesswire.comNorges Bank Acquires Shares of 204,361 Alumis Inc. (NASDAQ:ALMS)Norges Bank acquired a new position in shares of Alumis Inc. (NASDAQ:ALMS - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 204,361 shares of the company's stock, valued at approximately $1,606,000. Norges Bank owned about 0.43% of Alumis atApril 14, 2025 | marketbeat.comAlumis Inc. (NASDAQ:ALMS) Receives Average Recommendation of "Buy" from BrokeragesShares of Alumis Inc. (NASDAQ:ALMS - Get Free Report) have been given a consensus rating of "Buy" by the nine research firms that are presently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating tApril 12, 2025 | marketbeat.com3 Biopharmaceutical Stocks Bucking the Sell-OffThree biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence.April 10, 2025 | marketbeat.comAlumis Insider Trading Activity | NASDAQ:ALMS | BenzingaApril 10, 2025 | benzinga.comAlumis: Biotech's Stock Gains >100% In A Month - But Risk Of Failure Is HighApril 8, 2025 | seekingalpha.comAlumis and ACELYRIN announce definitive merger planApril 6, 2025 | investing.comMartin Babler Buys 15,650 Shares of Alumis Inc. (NASDAQ:ALMS) StockAlumis Inc. (NASDAQ:ALMS - Get Free Report) CEO Martin Babler bought 15,650 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The stock was purchased at an average price of $6.44 per share, with a total value of $100,786.00. Following the completion of the purchase, the chief executive officer now owns 106,454 shares in the company, valued at approximately $685,563.76. This trade represents a 17.23 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.April 5, 2025 | marketbeat.comInsider Buying: Alumis Inc. (NASDAQ:ALMS) Director Buys 16,104 Shares of StockAlumis Inc. (NASDAQ:ALMS - Get Free Report) Director Alan Colowick bought 16,104 shares of the stock in a transaction that occurred on Tuesday, April 1st. The shares were acquired at an average cost of $6.97 per share, with a total value of $112,244.88. Following the completion of the purchase, the director now owns 16,104 shares in the company, valued at $112,244.88. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.April 5, 2025 | marketbeat.comInsider Buying: Alumis Independent Director Bought US$130k Of SharesApril 5, 2025 | finance.yahoo.comAlumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed MergerApril 4, 2025 | globenewswire.comAlumis Inc. (NASDAQ:ALMS) CEO Acquires $100,786.00 in StockApril 4, 2025 | insidertrades.comAlumis (NASDAQ:ALMS) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Alumis in a research note on Wednesday.March 27, 2025 | marketbeat.comLeerink Partnrs Predicts Alumis' Q2 Earnings (NASDAQ:ALMS)Alumis Inc. (NASDAQ:ALMS - Free Report) - Investment analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Alumis in a research note issued to investors on Sunday, March 23rd. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share ofMarch 27, 2025 | marketbeat.comAlumis, Kaken Pharmaceutical enter ESK-001 collaboration and licensing agreementMarch 27, 2025 | markets.businessinsider.comAlumis Inc. Reports 2024 Results and Strategic MergerMarch 27, 2025 | tipranks.comQ1 Earnings Estimate for Alumis Issued By Leerink PartnrsAlumis Inc. (NASDAQ:ALMS - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Alumis in a research note issued on Sunday, March 23rd. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of ($1.46) for the quarter. The conMarch 26, 2025 | marketbeat.comStrategic Partnerships and Financial Projections Bolster Buy Rating for Alumis Inc.March 26, 2025 | tipranks.comAlumis stock soars on Japan dermatology dealMarch 25, 2025 | investing.comAlumis rises on licensing deal with Japan’s KakenMarch 25, 2025 | msn.comPositive Buy Rating for Alumis Inc. Driven by Promising TYK2 Inhibitors and Strategic AdvancementsMarch 25, 2025 | tipranks.comAlumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in JapanMarch 25, 2025 | globenewswire.comFY2025 EPS Estimates for Alumis Cut by Cantor FitzgeraldAlumis Inc. (NASDAQ:ALMS - Free Report) - Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for shares of Alumis in a report released on Thursday, March 20th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will post earningsMarch 24, 2025 | marketbeat.comHC Wainwright Issues Negative Forecast for Alumis EarningsAlumis Inc. (NASDAQ:ALMS - Free Report) - Research analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for Alumis in a report issued on Thursday, March 20th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($1.29) per share forMarch 24, 2025 | marketbeat.comAlumis' (ALMS) "Overweight" Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating on shares of Alumis in a research report on Thursday.March 21, 2025 | marketbeat.comAlumis Inc. Reports Phase 2 and Phase 1 Clinical Data, Announces Merger Agreement with ACELYRIN, and Highlights 2024 Financial ResultsMarch 21, 2025 | nasdaq.comThursday’s 10 Worst-Performing StocksMarch 21, 2025 | insidermonkey.comAlumis (NASDAQ:ALMS) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $15.00 target price (down from $19.00) on shares of Alumis in a report on Thursday.March 21, 2025 | marketbeat.comAlumis Inc.: Alumis Reports Year End 2024 Financial Results and Highlights Recent AchievementsMarch 20, 2025 | finanznachrichten.deAlumis price target lowered to $15 from $19 at H.C. WainwrightMarch 20, 2025 | markets.businessinsider.comOppenheimer Sticks to Their Buy Rating for Alumis Inc. (ALMS)March 20, 2025 | markets.businessinsider.comAlumis Reports Year End 2024 Financial Results and Highlights Recent AchievementsMarch 19, 2025 | globenewswire.comAcelyrin adopts poison pill as Tang Capital Partners raises stakeMarch 13, 2025 | msn.comDrug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investorMarch 13, 2025 | bizjournals.comAlumis Inc. (ALMS) Receives a Buy from H.C. WainwrightMarch 11, 2025 | markets.businessinsider.comAlumis announces data from the OLE of its Phase 2 STRIDE trialMarch 10, 2025 | markets.businessinsider.comHow a skin drug trial could help Peninsula biotech pull off key mergerMarch 10, 2025 | bizjournals.comAlumis Inc. (ALMS) Receives a Buy from OppenheimerMarch 10, 2025 | markets.businessinsider.comAlumis' (ALMS) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $19.00 target price on shares of Alumis in a research report on Monday.March 10, 2025 | marketbeat.comAlumis to Present at Leerink's 2025 Global Healthcare ConferenceMarch 10, 2025 | globenewswire.comPromising Efficacy of Alumis Inc.’s ESK-001 in Psoriasis Treatment Boosts Market Position and Buy RatingMarch 10, 2025 | tipranks.com Get Alumis News Delivered to You Automatically Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter. Email Address ALMS Media Mentions By Week ALMS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALMS News Sentiment▼0.320.73▲Average Medical News Sentiment ALMS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALMS Articles This Week▼134▲ALMS Articles Average Week Get Alumis News Delivered to You Automatically Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DYN News WVE News ETNB News COLL News MLYS News GYRE News RCUS News ELVN News ZYME News CMRX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALMS) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALMS Stock Free ALMS Stock Alerts